palifermin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
fibroblast growth factors 4804 162394-19-6

Description:

MoleculeDescription

Synonyms:

  • QMS40680K6
  • palifermin
  • kepivance
  • 24-163 fibroblast growth factor 7 (human)
  • 24-163-Keratinocyte growth factor (human)
A fibroblast growth factor that is a specific mitogen for EPITHELIAL CELLS. It binds a complex of HEPARAN SULFATE and FIBROBLAST GROWTH FACTOR RECEPTOR 2B.
  • Molecular weight: 16279.90
  • Formula: C724H1147N203O206S9
  • CLOGP:
  • LIPINSKI: None
  • HAC: 409
  • HDO: 234
  • TPSA: 6730.23
  • ALOGS:
  • ROTB: 563

Drug dosage:

DoseUnitRoute
4.20 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2004 FDA BIOVITRUM AB

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mucosal inflammation 47.42 46.01 17 331 49357 42571630

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Mucosal inflammation 84.01 56.85 24 298 96117 110492860

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AF08 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Detoxifying agents for antineoplastic treatment
FDA CS M0168688 Fibroblast Growth Factor 7
FDA EPC N0000175671 Mucocutaneous Epithelial Cell Growth Factor
FDA PE N0000175675 Increased Epithelial Proliferation
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:64946 anti-HIV agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

V03AF Detoxifying agents for antineoplastic treatment 10 drugs
amifostineargininedexrazoxaneglucarpidaseleucovorinlevofolinic acidlysinemesnarasburicasetrilaciclib

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Mucositis following radiation therapy indication 109257007
Drug-induced mucositis indication 403666006
Prevention of Radiation Therapy-Induced Mucositis indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Fibroblast growth factor receptor 2 Kinase AGONIST DRUG LABEL DRUG LABEL

External reference:

IDSource
QMS40680K6 UNII
D05338 KEGG_DRUG
4024900 VUID
N0000179582 NUI
4024900 VANDF
C0677829 UMLSCUI
CHEBI:749597 CHEBI
CHEMBL1201821 ChEMBL_ID
DB00039 DRUGBANK_ID
D051523 MESH_DESCRIPTOR_UI
8186 INN_ID
6954 IUPHAR_LIGAND_ID
196319 RXNORM
19097 MMSL
63977 MMSL
d05417 MMSL
008779 NDDF
416470008 SNOMEDCT_US
416572003 SNOMEDCT_US
417092008 SNOMEDCT_US
417550009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KEPIVANCE HUMAN PRESCRIPTION DRUG LABEL 1 66658-113 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5.16 mg INTRAVENOUS BLA 24 sections